Please assess the completion status of the following clinical trial:

Trial Title: Improving PRegnancy Outcomes With PReVEntive Therapy in Africa-2 (IMPROVE-2)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* HIV-infected pregnant women between 16-28 weeks' gestation~* Viable singleton pregnancy~* On or eligible for cARTs and CTX~* A resident of the study area~* Willing to adhere to scheduled and unscheduled study visit procedures~* Willing to deliver in a study clinic or hospital~* Provide written informed consent~Exclusion Criteria:~* Multiple pregnancies (i.e. twin/triplets)~* HIV-negative or HIV status unknown~* Known heart ailment~* Severe malformations or non-viable pregnancy if observed by ultrasound~* Participants with advanced HIV-disease at WHO clinical stage 3 and 4~* Confirmed or suspected TB infection,~* Unable to give consent~* Known allergy or contraindication to any of the study drugs

- Gender: FEMALE
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- CTX-alone (Type: PLACEBO_COMPARATOR): Daily, one double-strength tablet of 160mg of sulfamethoxazole and 800mg of trimethoprim plus monthly placebo-DP, given as a fixed dose of 3 placebo-DP tablets daily for three days until delivery.
- CTX-DP (Type: EXPERIMENTAL): Daily, one double-strength tablet of 160mg of sulfamethoxazole and 800mg of trimethoprim plus monthly DP, given as a fixed dose of 3 tablets (40 mg of dihydroartemisinin and 320 mg of piperaquine) daily for three days until delivery.

Based on this trial design, predict the completion outcome and termination type (if applicable).